Multivalent scFv via Alkyne-Azide Cycloaddition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing multivalent single-chain fragments (scFv) are limited by poor pharmacokinetics, low throughput, high cost, and distorted folding, which reduces their specificity and affinity for tumor-associated antigens, hindering their effectiveness in cancer therapy.
Innovation Solution
A method involving alkyne-azide 1,3-dipolar cycloaddition is used to covalently attach scFv components, forming multivalent scFv constructs with improved valency and specificity by creating conjugate proteins through 1,2,3-triazole formation, allowing for site-specific cross-linking and increased affinity for tumor-associated antigens like MUC-1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If multivalent scFv are prepared by manipulating polypeptide linker length, then multivalent structure is achieved, but folding is distorted and specificity is reduced
Solution Approach 1:
The invention divides the scFv into separate monovalent units that are later assembled into multivalent structures through chemical cross-linking, allowing each unit to fold correctly independently while achieving the desired multivalency through controlled linkage
Solution Approach 2:
The patent uses chemical cross-linking agents as intermediaries to join scFv units, replacing the problematic direct polypeptide linker manipulation with a chemical bridge that preserves protein folding while enabling multivalent assembly
2Reliability
If multivalent scFv are prepared by anchoring on multimeric affinity reagents, then binding affinity is improved, but pharmacokinetics are poor and throughput is low
Solution Approach 1:
The invention enables scFv units to self-assemble into multivalent structures through chemical cross-linking without requiring external multimeric affinity reagents, thereby improving throughput while maintaining binding affinity through controlled self-organization
Solution Approach 2:
The patent changes the approach from using pre-formed multimeric reagents to using chemical cross-linking parameters (cross-linker concentration, incubation conditions) to control multivalent assembly, improving both affinity and productivity
3Quantity of substance
If chemical cross-linking using bi-functional linkers is used, then multivalent structure is formed, but product yields are limited
Solution Approach 1:
The invention introduces reactive groups at specific locations on the scFv structure (such as lysine residues or engineered cysteines) to enable controlled cross-linking, improving yield by localizing the cross-linking reaction to specific sites rather than relying on random bi-functional linker binding
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the binding affinity and specificity of scFv constructs for tumor-associated antigens, leading to improved pharmacokinetics and increased tumor targeting efficacy, with higher yields and reduced steric hindrance, thereby enhancing cancer therapy outcomes.
Implementation Method 1
contacting a first scFv component having from one to eight attached alkyne moieties with a second scFv component having an attached linking group with a terminal azide moiety under conditions sufficient for 1,2,3-triazole formation to occur
Data Source
AI summary
The present invention provides for a practical, universal and efficient method to ligate two large macromolecules (e.g., proteins) using the alkyne-azide 1,3-dipolar cycloaddition reaction to produce a conjugated macromolecule, such as a multivalent scFv. The present invention also provides for conjugate macromolecules comprising a plurality of macromolecule components cross-linked through at least one linking group comprising at least one 1,2,3-triazole moiety, wherein at least 50 percent of the macromolecule components in the conjugate macromolecule has only one site available for cross-linking.